Described are stable topical formulations useful in the treatment of viral wart infection, demodex infection and bacterial infection of the skin, and genitalia and the method of treating viral wart infection, demodex infection and bacterial infection of the skin, and genitalia with said compositions.

Disclosed herein is a transdermal delivery system comprising galantamine or its salt as an active ingredient. Also provided are methods of delivering a therapeutically effective amount of galantamine to a subject for the treatment of a disease condition. The disease condition includes a neurological condition such as Alzheimer's disease. Kits including the transdermal delivery system and methods of making such delivery system are also provided.

Disclosed herein is a transdermal delivery system comprising galantamine or its salt as an active ingredient. Also provided are methods of delivering a therapeutically effective amount of galantamine to a subject for the treatment of a disease condition. The disease condition includes a neurological condition such as Alzheimer's disease. Kits including the transdermal delivery system and methods of making such delivery system are also provided.

The present invention provides a method of treating and/or preventing pulmonary hypertension in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a bioactive peptide preparation derived from at least one botanical source.

A method of treatment of a neuropathic pain by administering an andrographolide to the subject is provided. The andrographolide treatment may relief the symptom of neuropathic pain by reducing the astrocytic activity.

This invention relates to pharmaceutical formulations of gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate, a monophosphate derivative of the well-known oncology drug gemcitabine. In particular, the invention relates to formulations which comprise a polar aprotic solvent, preferably dimethyl acetamide (DMA). Formulations comprising these solvent provide therapeutically effective treatments of gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate. The invention also relates to methods of using said formulations and kits comprising said formulations.

This invention relates to pharmaceutical formulations of gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate, a monophosphate derivative of the well-known oncology drug gemcitabine. In particular, the invention relates to formulations which comprise a polar aprotic solvent, preferably dimethyl acetamide (DMA). Formulations comprising these solvent provide therapeutically effective treatments of gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate. The invention also relates to methods of using said formulations and kits comprising said formulations.

The present invention relates to subcutaneous formulations of anti-CD38 antibodies and their uses.

The present invention relates to subcutaneous formulations of anti-CD38 antibodies and their uses.

The present invention relates to subcutaneous formulations of anti-CD38 antibodies and their uses.